BioStem Technologies (FRA:0JQ) Marketable Securities: €0.00 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:0JQ BioStem Technologies Inc FRA:0JQ
36 GF Score
Price €2.56
! 2 Warning Signs
View Full Analysis

What is BioStem Technologies Marketable Securities?

BioStem Technologies FRA:0JQ -25.07% 36 Marketable Securities is €0.00 Mil as of Jun. 2026. GuruFocus rates FRA:0JQ with a GF Score™ of 36/100. The stock has 2 warning signs investors should review.

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price. BioStem Technologies's Marketable Securities for the quarter that ended in Jun. 2026 was €0.00 Mil.

BioStem Technologies  (FRA:0JQ) Marketable Securities Explanation

Marketable Securities are very liquid as they tend to have maturities of less than one year. Furthermore, the rate at which these securities can be bought or sold has little effect on their prices.

Please note, GuruFocus' Marketable Securities also includes "Other Short Term Investment".

BioStem Technologies Marketable Securities Related Terms

BioStem Technologies Marketable Securities Historical Data

* Premium members only.

The historical data trend for BioStem Technologies's Marketable Securities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

BioStem Technologies Marketable Securities Chart

BioStem Technologies Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Marketable Securities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

BioStem Technologies Quarterly Data
Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Sep21 Dec21 Mar22 Sep22 Dec22 Mar23 Sep23 Dec23 Sep24 Dec24 Jun25 Sep25 Jun26
Marketable Securities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
FRA:0JQ
36GF Score
BioStem Technologies Inc FRA:0JQ
Marketable Securities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

BioStem Technologies Marketable Securities Calculation

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price.

Frequently Asked Questions Learn more about Marketable Securities →
What does a Marketable Securities of €0.00 Mil mean?
BioStem Technologies (FRA:0JQ) has a Marketable Securities of €0.00 Mil as of Jun. 2026. Marketable securities are high-liquid securites not directly classified as cash or cash equivalents. View historical data on BioStem Technologies and its competitors.
Is BioStem Technologies' Marketable Securities too high?
BioStem Technologies' current Marketable Securities is €0.00 Mil. Overall, BioStem Technologies has a GF Score™ of 36/100, reflecting its overall financial health beyond just this single metric.
How does BioStem Technologies' Marketable Securities compare to ?
BioStem Technologies' Marketable Securities of €0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Marketable Securities for a Biotechnology company?
A good Marketable Securities depends on the Biotechnology industry context. However, Marketable Securities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Marketable Securities mean?
A high Marketable Securities can signal that a stock is expensive relative to its fundamentals. Marketable securities are high-liquid securites not directly classified as cash or cash equivalents. View historical data on BioStem Technologies and its competitors. BioStem Technologies's current Marketable Securities is €0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BioStem Technologies stock overvalued right now?
BioStem Technologies (FRA:0JQ) has a current Marketable Securities of €0.00 Mil. The current Marketable Securities is €0.00 Mil. BioStem Technologies' overall GF Score™ is 36/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Marketable Securities calculated?
Marketable Securities is calculated from a company's financial statements. For BioStem Technologies (FRA:0JQ), the current Marketable Securities is €0.00 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

BioStem Technologies Business Description

Comparable Companies
Other Exchanges BSEM:USA
Address 2836 Center Port Circle, Pompano Beach, FL, USA, 33064
BioStem Technologies Inc is a regenerative biotechnology company focused on harnessing elements of perinatal tissue and the body's innate biology to repair or reverse damage caused by a broad range of degenerative diseases. The company develops, manufactures, and sells tissue allografts for the wound care market with a focus on the treatment of diabetic, pressure, and venous ulcers. Utilizing its proprietary BioRetain processing method, it manufactures perinatal tissue allografts. The company offers a comprehensive portfolio of high-quality brands that are trademarked and include VENDAJE AC, AmnioWrap2, and Others. The company generates key revenue from VENDAJE AC.
36GF Score

Get the complete analysis for FRA:0JQ

Marketable Securities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€2.56
Price